Literature DB >> 33482916

Stenotrophomonas maltophilia bacteremia in children: risk factors and mortality rate.

Mohammed Alsuhaibani1, Alanoud Aljarbou2, Sahar Althawadi3, Abdulrahman Alsweed4, Sami Al-Hajjar4.   

Abstract

PURPOSE: Stenotrophomonas maltophilia (S. maltophilia) is an opportunistic and nosocomial pathogen that can cause an invasive and fatal infection, particularly in hospitalized and immunocompromised patients. However, little is known about the impact of S. maltophilia bacteremia in pediatric patients. Therefore, we aimed to identify risk factors for mortality, antibiotics susceptibility to S. maltophilia, and mortality rates in pediatric patients with S. maltophilia bacteremia.
METHODS: We conducted a retrospective cohort study by identifying all S. maltophilia positive blood cultures in the microbiology laboratory database between January 2007 and December 2018 from hospitalized pediatric patients (age 1-14 years). After identifying patients with S. maltophilia bacteremia, medical charts were reviewed for demographics, clinical data, and outcomes within seven days of bacteremia diagnosis. Risk factors associated with mortality in S. maltophilia bacteremia patients were determined using univariate and multivariate analyses.
FINDINGS: Sixty-eight pediatric patients with S. maltophilia bacteremia were identified. All infections were nosocomial infections, and (88.2%) bacteremia cases were catheter-related bloodstream infections. On multivariate analysis, ICU admission prior to bacteremia episode and neutropenia were the major risk factors associated with mortality. S. maltophilia was the most susceptible to trimethoprim and sulfamethoxazole (TMP/SMX, 94.1%), followed by levofloxacin (85.7%). The overall mortality rate within seven days of S. maltophilia bacteremia diagnosis was 33.8%.
CONCLUSION: S. maltophilia bacteremia is a devastating emerging infection associated with high mortality among hospitalized children. Therefore, early diagnosis and prompt management based on local susceptibility data are crucial. Various risk factors, especially ICU admission prior to bacteremia episode and neutropenia, are associated with S. maltophilia bacteremia mortality.

Entities:  

Keywords:  Bacteremia; Bloodstream infections; Children; Stenotrophomonas maltophilia; Trimethoprim-sulfamethoxazole

Year:  2021        PMID: 33482916      PMCID: PMC7825200          DOI: 10.1186/s13756-021-00888-w

Source DB:  PubMed          Journal:  Antimicrob Resist Infect Control        ISSN: 2047-2994            Impact factor:   4.887


  31 in total

1.  Stenotrophomonas maltophilia: rare cause of meningitis.

Authors:  Cátia Rodrigues Correia; Sara Tavares Ferreira; Paula Nunes
Journal:  Pediatr Int       Date:  2014-08       Impact factor: 1.524

2.  Attributable mortality of Stenotrophomonas maltophilia bacteremia.

Authors:  Esin Senol; Jeffrey DesJardin; Paul C Stark; Laurie Barefoot; David R Snydman
Journal:  Clin Infect Dis       Date:  2002-05-24       Impact factor: 9.079

3.  Antibiotic resistance among clinical isolates of Stenotrophomonas maltophilia at a teaching hospital in Riyadh, Saudi Arabia.

Authors:  Tahir Naeem; Muhammad Absar; Ali M Somily
Journal:  J Ayub Med Coll Abbottabad       Date:  2012 Apr-Jun

4.  Stenotrophomonas maltophilia infection among young children in a cardiac intensive care unit: a single institution experience.

Authors:  Ciji Arthur; Xinyu Tang; Jose R Romero; Jeffrey G Gossett; Nada Harik; Parthak Prodhan
Journal:  Pediatr Cardiol       Date:  2014-10-08       Impact factor: 1.655

Review 5.  Microbiological and clinical aspects of infection associated with Stenotrophomonas maltophilia.

Authors:  M Denton; K G Kerr
Journal:  Clin Microbiol Rev       Date:  1998-01       Impact factor: 26.132

6.  Stenotrophomonas maltophilia bacteremia in pediatric patients-- a 10-year analysis.

Authors:  Ping-Sheng Wu; Chun-Yi Lu; Luan-Yin Chang; Po-Ren Hsueh; Ping-Ing Lee; Jong-Min Chen; Chin-Yun Lee; Pei-Chun Chan; Po-Young Chang; Tsao-Ton Yang; Li-Min Huang
Journal:  J Microbiol Immunol Infect       Date:  2006-04       Impact factor: 4.399

7.  Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies.

Authors:  A Micozzi; M Venditti; M Monaco; A Friedrich; F Taglietti; S Santilli; P Martino
Journal:  Clin Infect Dis       Date:  2000-10-04       Impact factor: 9.079

8.  Stenotrophomonas maltophilia: an emerging opportunist human pathogen.

Authors:  W John Looney; Masashi Narita; Kathrin Mühlemann
Journal:  Lancet Infect Dis       Date:  2009-05       Impact factor: 25.071

9.  Risk Factors Associated with Stenotrophomonas maltophilia Bacteremia: A Matched Case-Control Study.

Authors:  Kosuke Sumida; Yong Chong; Noriko Miyake; Tomohiko Akahoshi; Mitsuhiro Yasuda; Nobuyuki Shimono; Shinji Shimoda; Yoshihiko Maehara; Koichi Akashi
Journal:  PLoS One       Date:  2015-07-24       Impact factor: 3.240

10.  Emergence of Stenotrophomonas maltophilia nosocomial isolates in a Saudi children's hospital. Risk factors and clinical characteristics.

Authors:  Jobran M Alqahtani
Journal:  Saudi Med J       Date:  2017-05       Impact factor: 1.484

View more
  4 in total

Review 1.  Clinical challenges treating Stenotrophomonas maltophilia infections: an update.

Authors:  Maria F Mojica; Romney Humphries; John J Lipuma; Amy J Mathers; Gauri G Rao; Samuel A Shelburne; Derrick E Fouts; David Van Duin; Robert A Bonomo
Journal:  JAC Antimicrob Resist       Date:  2022-05-05

2.  Three-year evaluation of the nosocomial infections in pediatrics: bacterial and fungal profile and antimicrobial resistance pattern.

Authors:  Mehrnoush Afsharipour; Shima Mahmoudi; Hojatollahh Raji; Babak Pourakbari; Setareh Mamishi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2022-02-16       Impact factor: 3.944

3.  Risk Factors for Mortality in Hospitalized Patients with Stenotrophomonas maltophilia Bacteremia.

Authors:  Jiyong Jian; Zeqiang Xie; Liang Chen
Journal:  Infect Drug Resist       Date:  2022-07-21       Impact factor: 4.177

4.  Pathogenic potential of bacteria isolated from commercial biostimulants.

Authors:  Daniela Bulgari; Silvia Filisetti; Matteo Montagna; Emanuela Gobbi; Franco Faoro
Journal:  Arch Microbiol       Date:  2022-02-04       Impact factor: 2.552

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.